Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SAN FRANCISCO–(BUSINESS WIRE)–
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York.
A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology has exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831302197/en/
Media Contact
Caren Scannell
Director, Communications
[email protected]
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
[email protected]
KEYWORDS: California New York United States North America
INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Oncology
MEDIA:
| Logo |
 |